To exchange assets for shares of Sea King biological "blood transfusion" H-share subsidiaries

Sea King Biology for its shares listed in the holding subsidiary of the Sea Wang Yingtorong is "Care plus", in order to enhance its profitability, Sea King Biology decided to take its sea Wang Fu Laixi drug 80% stake into the sea Wang Yingtorong. Sea King Biological Disclosure today, the company and the wholly-owned subsidiary Sea King Pharmaceutical Industry agreed in the sea Wang Yingtorong can be successfully issued and placing 189 million new foreign shares (H shares), and other conditions, the company holds the sea Wang Fu Laixi drug 75% Equity, Sea King pharmaceutical Wang Fu Laixi Drug Holdings 5% stake, a total of 80% of the sea Wang Fu Laixi drug ownership transfer to Haiwing Intron,　　The total transfer price of 433.6 million yuan, Haiwing Intron will be RMB 0.8 yuan/share price to the Sea King biological distribution of 542 million new shares of the way, to meet the company and the Sea King pharmaceutical industry, the above-mentioned transfer of shares. It is reported that the Hai Wangfo drug currently holds the Fuzhou Sea King gold like Chinese Medicine Pharmaceutical Co., Ltd. 95% stake, holding Fuzhou Fu Pharmaceutical Co., Ltd. 90% Equity, and through the gold-like Chinese medicine holding 10% stake in Fu Medicine medicine.　　Hai Wangfo drug 160 million yuan in January-April this year, a net profit of 19.0662 million yuan. Sea King Biological said, the transaction does not affect the company's Wang Fu Laixi drug control, but will make the company in the sea Wang Fu Laixi drug interests have declined. This transaction will not have a significant impact on the 2010-year performance of the Sea King, given that the transaction is traded in a consolidated statement and the actual delivery date is shorter than the end of the period.